Plain-English translation of NCT07444801 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is studying whether a medication called can help people with moderate-to-severe eczema that involves the genital area. Eczema in this sensitive region can be particularly uncomfortable and distressing, and this study wants to see how effective the medication is at improving symptoms and quality of life over the course of a year.
Eczema affecting the genital region is a specific and often underrecognized problem that can cause significant discomfort and emotional distress. This trial exists to gather real-world evidence about whether this medication can effectively treat this particular type of severe eczema.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as part of your regular medical care over 52 weeks (one year). You'll have clinic visits at the start of treatment, and then at 4 weeks, 16 weeks, 24 weeks, and 52 weeks, where researchers will collect information about how your skin is responding and how you're feeling. The study takes place at two medical centers in Germany and involves straightforward follow-up appointments alongside your normal treatment.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Germany